

CONFERENCE
HANDBOOK

Brisbane Cancer Conference

28–29 November 2019

Brisbane Convention and Exhibition Centre



Conference Sponsors

Platinum Sponsor



Gold Sponsor



Silver Sponsors




Bronze Sponsors



Pharma and Biotech Donations



Institution Donations





Welcome



Dear Colleagues,

Welcome to the 6th Annual Brisbane Cancer Conference. With the establishment of the Brisbane Diamantina Health Partners as an NHMRC Advanced Health Research and Translation Centre, this meeting is an opportunity to draw together cancer researchers in Brisbane and Queensland to advance collaborative efforts in cancer research. The meeting comprises plenary lectures and workshops on recent scientific, technological, nursing and medical advances in the diagnosis and treatment of malignant disease.

On Thursday 28th November the meeting will start with Breast Cancer, Prostate Cancer, Survivorship and Immunotherapy symposia running from 8am–12pm in the morning. There will be AstraZeneca and Roche satellite symposia at lunch-time followed by plenary lectures from 2–4pm and subsequently workshops in these areas running from 4.30–6.00pm. Further MSD symposium will be held from 6.15–7.15pm.

The Gala dinner will be held on Thursday evening offering the opportunity to socialise with colleagues particularly from other institutions in the city and from Queensland.

The all-day session on Friday 29th November will include plenary lectures followed by tumour-site specific and scientific workshops in the morning and afternoon. A key session will be lectures by oncology researchers focussed on collaborative research in Brisbane and Queensland.

In the region of 1,000 delegates attended the event last year demonstrating the value of a truly multi-disciplinary annual Queensland Translational Cancer Conference in Brisbane.

This conference is made possible through the support of the PA Research Foundation and Brisbane Diamantina Health Partners, our many sponsors, the time and effort of the chairs who put the workshops together and also the QUT Cancer and Ageing Research Program (CARP) team who look after the day to day running of the conference.

Best wishes for what should be an enjoyable and fulfilling two days.

Yours sincerely,

Professor Ken O'Byrne
Consultant Medical Oncologist
Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology



Conference Program

DAY
1

Thursday 28 November 2019

Opens 7.00am Registration

Symposia (8.00am–12.00pm)

Survivorship (Supported by Roche)

Room A2

Chairs: Ray Chan, David Wyld on behalf of Queensland Collaborative for Cancer Survivorship

8.00am	Think Tank: Establishing the Research Agenda for Supportive Cancer Care in Queensland 2021-2024 Objectives: The objectives of this think tank are to gather all clinicians and researchers who are interested in shaping and informing Queensland's future supportive care delivery, and establish research priorities for supportive care in Queensland. Panelists: David Wyld, Raymond Chan, Vanessa Beesley, Sandi Hayes, Leanne Stone, Marina Reeves, Jane Turner, Patsy Yates
--------	---

Prostate Cancer (Supported by Janssen)

Room B1

Chairs: Ian Vela, Colleen Nelson

8.00am	TheraP trial, new Lu-PSMA Movember trial – Arun Azad
8.30am	Treatment induced neuroendocrine prostate cancer – Brett Hollier/Marianna Volpert
9.00am	Intersection of metabolic syndrome in prostate cancer – Jenni Gunter
9.30am	Gap4: exercise trial in metastatic castrate resistant prostate cancer – Natalie Vear
10.00am	Morning tea
10.30am	Matchup trial – Paul Hodges
10.50am	Predictive therapeutic screening in high risk localised cancer – Saeid Alinzhad
11.10am	Mock Queensland Molecular Tumor Board meeting – Case presentation: Ian Vela – Genomics analysis of case: Paul Leo – Discussion: Arun Azad, Kumar Gogna, Ian Vela, Paul Leo

Immuno-oncology (Supported by AstraZeneca)

Rooms B2 and B3

Chairs: Mark Smyth, Rajiv Khanna, Riccardo Dolcetti

8.00am	Applications of genomics to cancer immunotherapy – Felicity Newell
8.30am	Advances in Immunobiology; CD39 targeted therapy and adenosine – Mark Smyth
8.55am	The emergence of natural killer cells as a major target in immunotherapy – Fernando Fonseca-Guimaraes
9.15am	Enhancing solid tumour CAR-T cell immunotherapy using Nextgen Cancer Vaccines – Riccardo Dolcetti
9.35am	Mechanisms of resistance to Checkpoint inhibitors; DNAM-1 loss and CD155 – Tobi Bald
10.00am	Morning tea
10.30am	Advances in the clinic – Lung cancer: Rahul Ladwa – Skin cancer: Wen Xu
11.00am	Radiotherapy as an immune adjuvant – Gishan Ratnayake
11.20am	Epigenetics and immune checkpoint blockade – Sudha Rao
11.40am	Adenosine and rituximab in B cell lymphoma – Kyohei Nakamura

Breast Cancer (Supported by Novartis)

Boulevard Room

Chairs: Rik Thompson, Katharine Cuff, Fiona Simpson

8.00am	Novel strategies to overcome endocrine resistance in breast cancer – Elgene Lim
8.30am	Translational Breast Cancer Genomics – Amy McCart-Reed
8.55am	Role of neoadjuvant chemotherapy in breast cancer surgery – Ben Green
9.15am	Immuno-oncology in Breast Cancer – Marcin Dzienis
9.40am	Getting to the heart of the matter: modern radiation therapy strategies – Margot Lehman
10.00am	Morning tea

Chairs: Eliza Whiteside, Margot Lehman

10.30am	PARP-inhibition from a Translational Perspective – Kum Kum Khanna
10.55am	What does breast density means in terms of mammography screening – Tom Lloyd
11.15am	Survivorship: Supporting quality of life – Heather Green
11.35am	Optimising Care: supporting women with metastatic breast cancer through diet and exercise – Marina Reeves
12.00pm	Refreshments

Conference Program

DAY
1

Thursday 28 November 2019

12.00pm AstraZeneca and Roche Pharmaceuticals sponsored lunch

Lunchtime Symposia (12.15pm–1.45pm)

Boulevard Room

AstraZeneca Pharmaceuticals

Chair: Michelle Murphy

Theme: Optimising Molecular Testing to Improve Outcomes for Patients with Lung Cancer

12.15pm	Tissue acquisition: Principles and best practice to maximise diagnostic yield – David Fielding
12.22pm	The evolving complexity of treatment decision making in lung cancer – Zarnie Lwin
12.30pm	Case presentation – Zarnie Lwin
12.35pm	Panel Discussion: David Fielding, Zarnie Lwin, Caroline Cooper, Chiyan Lau, Glenn Francis

Roche Pharmaceuticals

Chair: Nicole McCarthy

Title: Immunotherapy in triple negative breast cancer

1.00pm	Welcome and introduction: Nicole McCarthy
1.05pm	Immunotherapy in mTNBC – Vladimir Andelkovic
1.15pm	Testing for PD-L1 in Breast Cancer – Sunil Lakhani
1.25pm	Discussion/Q&A

1.30pm Arrival refreshments

Plenary Lectures (2.00pm–4.00pm)

Boulevard Auditorium

Chairs: Ross Young, Damian Topp

2.00pm	Moving beyond rhetoric – implementation of shared follow-up care with GPs? – Ray Chan
2.20pm	Where we are with biobanking in Brisbane? – Sunil Lakhani
2.40pm	CAR-T cells – a revolutionary treatment' disruptive technology – Siok Tey
3.00pm	Genomic Confidence amongst Queensland Cancer Physicians – Aideen McInerney-Leo
3.20pm	Guidelines on exercise in cancer – Sandi Hayes
3.40pm	Innovations in patient-reported outcomes in Queensland – Bena Brown

4.00pm Refreshments

Parallel Workshops (4.30pm–6.00pm)

Clinical trials

Arbour Level, Room A1

Chairs: Adam Stoneley, Suzanne Elliott

4.30pm	Clinical trial organisations updates from the 5 CT:IQ projects – Leanne Weekes, CT:IQ
	– Toolkit for involving Consumers
	– eConsent
	– Early Phase trials
	– Recruitment
	– Biomarker-directed therapies

Round table training session

5.15pm	Trials and tribulations of phase I oncology studies – Suzanne Elliott
5.45pm	ClinTrial Refer Version 2 – Adam Stoneley

Conference Program

DAY
1

Thursday 28 November 2019

Parallel Workshops (4.30pm–6.00pm)

Biobanking

Arbour Level, Room A2

Chairs: Euan Walpole, Sunil Lakhani

Theme: Biobanking Perspectives

4.30pm	Clinical and Biomedical Research, Queensland Childrens Hospital – Andy Moore
4.50pm	Scientific Services, QIMRBerghofer – Leon Scott
5.10pm	Gold Coast Biobank, Griffith University – Shirley Wee
5.30pm	Surgical Oncology Research Group, UQ – Vanessa Bonazzi
5.45pm	Discussion

Genomics and Commercialisation

Boulevard Level, Room B1

Chairs: John Pearson, Derek Richard

4.30pm	The Australian Genomics Hereditary Cancer Flagship (ICCon) – Uwe Dressel
4.45pm	Machine Learning and Clinical Genomics – Cameron Bean
5.00pm	Single Cell Sequencing and Cancer genomics – Josh Lee
5.15pm	Long Read Sequencing and Cancer Genomics – Liam McIntyre
5.30pm	Pharmacogenomics in Oncology – Eric Lee
5.40pm	Illumina Diagnostic Platforms – Anthony Beckhouse
5.50pm	Discussion/Q&A

Survivorship

Boulevard Level, Room B2

Chairs: Ray Chan, David Wyld

Theme: Cancer-related fatigue – why is it still one of patients top unmet supportive care needs and what are we doing about it?

4.30pm	Setting the scene – Cancer-Related Fatigue – Ray Chan
4.40pm	What do the unmet needs data tell us? – Vanessa Beesley
4.55pm	How can screening contribute to meeting the need? – Bena Brown
5.10pm	Cancer-related Fatigue – Is exercise done to death yet? What works? – Elizabeth Pinkham
5.25pm	Educational interventions for management of cancer-related fatigue in adults – Amanda Pigott
5.40pm	Panel Discussion – What should the next steps be in advancing the science of cancer related fatigue – Chaired by David Wyld and Ray Chan

GU malignancies

Boulevard Level, Room B3

Chair: Jeff Goh, Elizabeth Williams

Theme: Clinical research in urological malignancies

4.30pm	Optimal management and clinical trials in localised bladder cancer – Ian Vela
4.45pm	Testing drug responsiveness in bladder cancer patient derived organoids – Patrick Thomas
5.00pm	Clinical trials in advanced bladder and renal cell cancer – Jeff Goh
5.30pm	Bladder cancer in the era of molecular subtyping – Olga Kondrashova

Haematology-oncology

Boulevard Room

Chairs: Sally Mapp, Andrea Henden

Theme: Personalized therapies in Haematology Oncology

4.30pm	Unique lymphoma subtypes – Colm Keane
5.00pm	Targeting control of cell cycle enhances activity of conventional chemotherapy on chemotherapy-resistant acute myeloid leukaemia – Victoria Ling
5.30pm	Minimal residual disease in paediatric acute myeloid leukaemia – Sadia Afrin

MSD Symposia (6.15pm–7.15pm)

Boulevard Room

6.15pm	The role of Keytruda in combination with chemotherapy in patients with metastatic nSCLC without EGFR or ALK tumour aberrations – Kenneth O'Byrne
--------	--

7.15pm
'til late

Gala Dinner, Sky Room, Brisbane Convention and Exhibition Centre

Conference Program

DAY
2

Friday 29 November 2019

Opens 7.00am Registration

Plenary Lectures (8.00am–10.00am)

Boulevard Auditorium

Chairs: Michael Kimlin, Janet Hardy

8.00am	Modern management of brain metastases – Mark Pinkham
8.20am	Changing demographics and pattern of care in head and neck cancer: a statewide-population based analysis – Chris Daniels
8.40am	Targeting the DNA damage response in solid tumours – Jeff Goh
9.00am	A universal, cheap, screening test for cancer: Are we there yet? – Matt Trau
9.20am	Contribution of pharmacy to cancer research – Christine Carrington
9.40am	The future of voluntary assisted dying in Australia – Ben White

10.00am Tea and Coffee

Parallel Workshops (10.30am–12.00pm)

Pharmacy Research & Innovation Roundup

Arbour Level, Room A1

Chair: Dan McKavanagh

Theme: A summary of local research, projects, and improvements happening in cancer pharmacy

10.30am	Evaluation of systemic therapies for metastatic melanoma at PAH – a pragmatic study – Ian McPherson
10.45am	Pharmacy involvement in hyperthermic intraperitoneal chemotherapy (HIPEC) – Cathy Wilkinson
11.00am	Identifying the potential for errors when compounding parenteral cancer medicines: results from an observational audit – Marissa Ryan
11.15am	Drug Use Optimisation in Private Cancer Care: Challenges and Successes – Ella Raguz
11.30am	The PostMAN Clinic: A collaborative model of care for post BMT patients – Midori Nakagaki
11.45am	Discussion

3-D cancer models

Arbour Level, Room A2

Chair: Laura Bray

10.30am	Preclinical model of colorectal cancer – Vicki Whitehall
10.50am	Microfluidic systems for modelling heterogeneity in tumour drug response – Yi-Chin Toh
11.10am	Bladder cancer spheroids as a functional platform for personalised medicine – Patrick Thomas
11.25am	Matrix stiffness effects on calcium influx in breast cancer cells – Choon Leng So
11.40am	Bioengineered multi-cellular prostate cancer angiogenesis research 3D model – Anna Jaeschke

Brian tumours

Boulevard Level, Room B1

Chairs: Mark Pinkham, Brian Day, Sarah Olsen

Theme: Integration of brain tumours (primary and secondary) into the C-PAC rapid applied translational research program

10.30am	Vision for the CPAC initiative – Rik Thompson
10.38am	Overview of the brain stream – Bryan Day
10.46am	Progress on project so far – Ulrich Baumgartner
10.54am	Immunologic aspects – Riccardo Dolcetti
11.02am	3d models of melanoma brain metastases – Nik Haass
11.10am	Update of GBM-T cell therapy trial – Rajiv Khanna

Conference Program

DAY
2

Friday 29 November 2019

Parallel Workshops (10.30am–12.00pm)

11.18am	Update on overcoming blood brain barrier and liquid biopsy diagnostics – Simon Puttick
11.26am	Discussion

Immuno-oncology

Boulevard Level, Room B2

Chairs: Tobias Bald, Michelle Wykes

Theme: Novel approaches to immunotherapy

10.30am	Follicular cytotoxic T cells and IL-21 immunotherapy for cancer – Di Yu
10.42am	Adoptive infusion of genetically modified monocytes to target the immune-suppressive tumour microenvironment – Roberta Mazzieri
10.54am	Polarizing DC by blocking ER stress – Indrajit Das
11.06am	Immune mechanisms of squamous cell carcinoma rejection – Zhen Zeng
11.18am	Clec9A targeting primes human tumour specific CD8+ T cells – Kristen Radford
11.30am	PDL-2: side kick or star? – Michelle Wykes
11.45am	Discussion

Thoracic Malignancies

Boulevard Level, Room B3

Chairs: Henry Marshall, Michelle Murphy, David Fielding

Theme: Optimising screening and molecular diagnostics

10.30am	International lung screen trial – Henry Marshall
10.45am	Radiology: optimisation of imaging protocols – Katrina Hopcraft
10.55am	Optimisation of biopsies for molecular diagnostics – David Fielding
11.05am	Integrating pathology with 'omics – Cameron Snell
11.15am	WES and large panel sequencing in lung cancer diagnostics – Paul Leo
11.25am	Circulating tumour cells – Joanna Kapeleris
11.35am	Adjuvant therapy strategies based on ctDNA detection – Kenneth O'Byrne
11.45am	Discussion/Q&A

Gynae-oncology

Boulevard Room

Chairs: Lew Perrin, Carlos Salomon Gallo

10.30am	To sentinel or not to sentinel in endometrial cancer – Jim Nicklin
10.40am	Genomic changes in young women with endometrial cancer – Nim Cabraal
10.50am	HIPEC and ovarian cancer Brisbane experience – Naven Chetty
11.00am	Robotic surgery – Sinead Barry
11.10am	CRISPR and its role in gynae cancers – Adi Idris
11.20am	Epidemiological trials in ovarian cancer: the proposed Vitamin D trial – Rachel Neale
11.30am	Exosomes and ovarian cancer – Carlos Saloman
11.40am	Lymphoedema trials update – Sandi Hayes
11.50am	Discussion

12.00 pm Lunch

Plenary Lectures (12.30pm–2.00pm)

Boulevard Auditorium

Chairs: David Waugh, Paul Clarke

12.30pm	C-PAC: a BDHP cancer research collaboration – Rik Thompson
12.50pm	The evolution of telemedicine trials – Sabe Sabesan
1.10pm	Improving Patient Experiences of Cancer Care – Patsy Yates
1.30pm	Brisbane Diamantina Health Partners and cancer research – Steven Lane

2.00pm Refreshments

Conference Program

DAY
2

Friday 29 November 2019

Parallel Workshops (2.30pm–4.00pm)

GI malignancies

Arbour Level, Room A1

Chair: Nick Lutton, Vicki Whitehall

2.30pm	Insights from 25 years of Managing Anal Cancer in Queensland – Glen Guerra
2.42pm	Decision-making in Rectal Cancer Treatment: Experience at PAH – Ho Nam Choi
2.54pm	Evolution of the Queensland Peritonectomy Service over 10 years – Wen Wong
3.06pm	Colorectal Cancer Clinical Trials at the RBWH – Melissa Eastgate
3.18pm	BRAF Mutant Colorectal Cancer – Vicki Whitehall
3.30pm	Genomics of Metastatic Colorectal Cancer – Ann-Marie Patch
3.42pm	Discussion: Brisbane Colorectal Cancer Working Group Proposal

Liquid biopsies

Arbour Level, Room A2

Chair: Matt Trau

2.30pm	DNA methylation-based diagnostics for cancer detection – Jason Ross
2.45pm	A 10-minute universal cancer test based on interfacial biosensing – Abu Sina
3.00pm	Extracellular vesicle-based liquid biopsies in cancer – Andreas Moller
3.15pm	Diagnostic Nanotechnologies for Liquid Biopsy-based Personalised Melanoma Treatment – Alain Wuethrich
3.30pm	CTC technology in liquid Biopsies – Arutha Kulasinghe
3.45pm	Discussion

Breast cancer

Boulevard Level, Room B1

Chair: Pete Simpson, Rik Thompson

2.30pm	Primitive epigenomic context underpins SOX10 involvement in tumour progression – Jodi Saunus
2.45pm	Guiding clinical choices to overcome a novel mechanism of chemoresistance – Adrian Wiegman
3.00pm	Developing a 3D model for the study of the breast tumour microenvironment – Laura Bray
3.15pm	Marizomib targets triple-negative breast cancer via dual blockade of proteasome activity and metabolic niche – Prahlad Raninga
3.30pm	A new combination strategy based on IFN α delivery and cancer vaccination to treat triple negative breast cancer metastasis – Roberta Mazzieri
3.45pm	Use of bar coded-multimers to de-risk the design and development of immunotherapies to treat breast cancer patients – Jazmina Gonzalez Cruz

Melanoma and skin cancer

Boulevard Level, Room B2

Chairs: Nikolas Haass, Helmut Schaidler, Jacinta Simmons

2.30pm	Shade auditing in Queensland – Nathan Downs
2.40pm	Development of a sun-smart uniform policy for Queensland schools – Jodie Antrobus
2.50pm	The Uveal Melanoma Genome – Peter Johansson
3.00pm	Mainstreaming CDKN2A testing in Dermatology Clinics: Are we ready yet? – Aideen McInerney-Leo
3.10pm	MAIT cells promote tumor initiation, growth and metastases via tumor MR1 – Juming Yan
3.20pm	Mitf, Brn2 and Axl: Modulators of melanoma drug resistance? – Jacinta Simmons
3.30pm	Bortezomib-induced immunogenic cell death enhances immune response in melanoma – Sheena Daignault
3.40pm	Enhancing immunotherapy response by epigenetic reprogramming in melanoma – Jason Lee
3.50pm	The role of endovascular progenitor cells in melanoma – Ghazaleh Hashemi

Conference Program

DAY
2

Friday 29 November 2019

Parallel Workshops (2.30pm–4.00pm)

Head and neck cancer

Boulevard Level, Room B3

Chairs: Chris Perry, Rahul Ladwa

2.30pm	Updates in trials for H&N cancer – Margaret McGrath
2.42pm	Current plastics techniques and concepts for H&N cancer patients – Milap Rughani
2.54pm	Mask anxiety for the person undergoing radiotherapy – Jodie Nixon
3.06pm	Natural history of oral human papillomavirus infection in Queensland – Annika Antonsson
3.18pm	Dissecting the role of salivary exosomes in HPV-driven oropharyngeal cancer – Kai Tang
3.30pm	Updates in CESTEM trial – Priscila Oliveira De Lima
3.42pm	Salivary screening for oropharyngeal cancers – Sarj Vasani
3.54pm	Discussion/Q&A

Palliative Care

Boulevard Room

Chairs: Ben Gunawan, Phillip Good

2.30pm	How important is genetic variation on response to methadone? – Alison Haywood
2.45pm	A qualitative study into patients' views of medicinal cannabis – Thomas Dinala
3.00pm	Introducing technology in supportive care Cancer – Kim Alexander
3.15pm	Muscle wasting in advanced cancer: could nutrition intervention still be effective? – Barbara Van der Meij
3.30pm	Efficacy of Exercise Interventions in Patients with Advanced Cancer – Tom Bailey
3.45pm	Discussion prompt list in paediatric palliative care – Anthony Herbert

4.00pm

Refreshments

Plenary session: focus on the future (4.15pm–5.15pm)

Boulevard Auditorium

Chairs: Frank Gannon, Michael Cleary

4.15pm	Kieran O'Brien, Siemens Healthineers	AI in Oncology
4.30pm	Terry Sweeney, IBM Watson	AI in Oncology
4.45pm	John Pearson, GenomiQa	Complex genomics for precision medicine
5.00pm	Discussion/Q&A	


5.15pm –
6.00pm

Wine and cheese


Venue Floor Plans




BRISBANE
convention
& exhibition
CENTRE



Boulevard Level



Arbour Level



Sponsor Floor Plan

Astrazeneca	10
Roche-Genentech	11
BMS	4
Janssen	9
MSD	12
Pfizer	7
Amgen	13
Astellas	6
Boehringer-Ingelheim	5
Ferring	15
ICON	8
Ipsen	1
Menarini	2
Merck	16
Novartis	18
Servier	14
Sullivan Nicolaides	17
Teva	3

Foundation Medicine	T2
GE Healthcare	T5
Illumina	T7
Mundipharma	T1
Sanofi	T6
Siemens	T3
Takeda	T4

brisbane diamantina
health partners

